Fast-track pathway for minimally invasive colorectal surgery with and without alvimopan (entereg)™: Which is more cost-effective?

American Surgeon

Volumn 79, Issue 6, 2013, Pages 630-633

  Kelley, Scott R ^a   Wolff, Bruce G ^a   Lovely, Jenna K ^b   Larson, David W ^a  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVIMOPAN; NONALVIMOPAN; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ANESTHESIA; ARTICLE; COLON TUMOR; COLORECTAL CANCER; COLORECTAL SURGERY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIETARY INTAKE; DRUG USE; FEMALE; GASTROINTESTINAL TRACT FUNCTION; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; IRRITABLE COLON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE SURGERY; OUTCOME ASSESSMENT; PATIENT CARE; POSTOPERATIVE PERIOD; SURGICAL APPROACH;

ADULT; COLON; COST-BENEFIT ANALYSIS; CRITICAL PATHWAYS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; PIPERIDINES; RECTUM; RETROSPECTIVE STUDIES; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TIME FACTORS;

EID: 84878219869     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Senagore AJ. Pathogenesis and clinical and economic consequences of postoperative ileus. Clin Exp Gastroenterol. 2010;3:87-9.
2. Wind J, Polle SW, Fung Kon Jin PH, et al. Systematic review of enhanced recovery programmes in colonic surgery. Br J Surg 2006;93:800-9.
3. Gouvas N, Tan E, Windsor A, et al. Fast-track vs standard care in colorectal surgery: a meta-analysis update. Int J Colorectal Dis 2009;24:1119-31.
4. Larson DW, Batdorf NJ, Touzios JG, et al. A fast-track recovery protocol improves outcomes in elective laparoscopic colectomy for diverticulitis. J Am Coll Surg 2010;211:485-9.
5. Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg 2008;143:1098-105.
6. Bell TJ, Poston SA, Kraft MD, et al. Economic analysis of alvimopan in North American Phase III efficacy trials. Am J Health Syst Pharm 2009;66:1362-8.
7. Vaughan-Shaw PG, Fecher IC, Harris S, Knight JS. A metaanalysis of the effectiveness of the opioid receptor antagonist alvimopan in reducing hospital length of stay and time to GI recovery in patients enrolled in a standardized accelerated recovery program after abdominal surgery. Dis Colon Rectum 2012;55:611-20.
8. Asgeirsson T, El-Badawi KI, Mahmood A, et al. Postoperative ileus: it costs more than you expect. J Am Coll Surg 2010;210:228-31.
9. Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004;240:728-34.
10. Delaney CP, Wolff BG, Viscusi ER, et al. Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. Ann Surg 2007;245:355-63.
11. Ludwig K, Viscusi ER, Wolff BG, et al. Alvimopan for the management of postoperative ileus after bowel resection: characterization of clinical benefit by pooled responder analysis. World J Surg 2010;34:2185-90.
12. Wolff BG, Delaney CP, Viscusi ER, et al. Alvimopan is associated with reduced hospital length of stay, lowered readmission rates, and decreased costs after bowel resection. Presented at the American Society of Health-System Pharmacists Summer Meeting and Exhibition; June 27, 2006; Orlando, FL.
13. Poston S, Broder MS, Gibbons MM, et al. Impact of alvimopan (Entereg) on hospital costs after bowel resection: results from a large inpatient database. P T 2011;36:209-20.